Medindia

X

New Research and Treatment Options for Millions Suffering Headaches and Chronic Pain to be Presented at 10th Annual Headache and Pain Conference

Thursday, May 29, 2008 General News J E 4
Advertisement
ANN ARBOR, Mich., May 28 Pain affects more Americans thandiabetes, heart disease and cancer combined. According to the NationalCenters for Health Statistics, pain affects 76.2 million people. The latestresearch into creating more effective treatment outcomes for people sufferingwith pain focuses on gender differences, the detrimental impact of certainmedications, and nerve and magnetic stimulation.

These areas are among the focus of presentations planned for the MichiganHead-Pain & Neurological Institute's (MHNI) 10th Annual Headache and PainConference. Leading experts from across the United States will join MHNIfounder Joel R. Saper, M.D., to present their latest findings.

The Michigan Head-Pain & Neurological Institute and Chelsea CommunityHospital are celebrating the 30th anniversary of their partnership byrecruiting a "who's who" of headache and pain management experts for theconference. Presenters include researchers from the Mayo Clinic, Universityof Florida, The Center for Pain Management at the University of Pennsylvania,the John R. Graham Headache Center in Boston, as well as the MedicalUniversity of Ohio.

Dr. Saper said, "The information to be presented is authoritative anduniquely applicable to the current state of headache and pain management.Every day we learn more about this debilitating public health problem. Themore data and treatment strategies we can provide to the public and to medicalprofessionals, the better prepared they will be to address these major painissues."

The 10th Annual Update in Headache and Pain Management conference willtake place Friday, May 30 from 8 a.m. - 6 p.m. at The Ritz-Carlton inDearborn, Mich. The conference is for health professionals interested in painand pain management. For registration, call (734) 677-6000, ext. 146 or visitwww.MHNI.com.

About MHNI

Michigan Head-Pain & Neurological Institute, based in Ann Arbor, Mich., iscelebrating its 30th anniversary. Noted neurologist and pain medicinespecialist Dr. Joel R. Saper founded MHNI in 1978 to pioneer headache researchand treatment. MHNI is considered one of the world's premier centers for headand neck pain management, providing comprehensive care to patients from aroundthe world suffering from headache and related painful disorders. MHNIpartners with Chelsea Community Hospital (CCH) where MHNI hospitalizes itsmost severely painful patients in its specialized headache unit. Dr. Saperand CCH developed the head pain treatment unit at CCH in 1978, forming thefirst hospital specialty program of its kind in the world.Information to be covered includes: -- New brain science on how pain killers can cause more pain and more headaches; -- The role of childhood stress and abuse and the subsequent development of adult chronic pain; -- The role of estrogen in making women more vulnerable than men to headaches; -- Gender differences in the perception and experience of pain; -- New treatment options for menstrual migraines; -- Information that certain pain killers reduce male testosterone and female ovarian hormones; -- Current update on fibromyalgia, including discussion of medications in research but not yet available; -- Possible value of certain antibiotics in controlling headaches; -- Potential new breakthrough therapies for headache and pain, including Transcranial Magnetic Stimulation and Subcutaneous Neurostimulation; -- How even appropriate medications for headache can make headaches worse; -- How certain pain killers, when given to younger patients, are more likely to cause dependency and tolerance than when given to older individuals; -- A focus on the parts of the brain that are involved in the development of headaches and other aspects of chronic pain; -- That the neck and the head are part of a neural circuit that c
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Novavax CEO to Present at FBR Capital Markets 12th...
S
Significant Barriers Prevent People with MS from F...